Skip to main content

Table 1 Overview of measures and time of assessment

From: Paris MEM: a study protocol for an effectiveness and efficiency trial on the treatment of traumatic stress in France after the 2015–16 terrorist attacks

Instrument

Variable

T0

Treatment sessions

T1

T2

T3

 

t1

t2

t3

t4

t5

t6

   

Demographics

Sociodemographic characteristics

X

         

PCL-S

PTSD symptom severity

X

x

x

x

x

x

x

X

X

X

CGI

Global patients’ condition

*

x

x

x

x

x

x

*

*

*

MINI-S

Diagnosis and comorbidities

X

      

X

X

X

PDI

Severity of trauma exposure

X

         

PDEQ

Peritraumatic dissociation

X

         

WHOQOL-BREF

Quality of life

X

      

X

X

X

EQ-5D-5 L

Quality of life

X

      

X

X

X

MEDEC

Health service utilization

X

      

X

X

X

HSCL-25

Anxiety and depressive symptoms

X

      

X

X

X

QFS

Social functioning

X

      

X

X

X

  1. *Assessed by a clinician blind to the patient’s treatment modality
  2. T0: baseline assessment
  3. T1: posttreatment assessment (week 7)
  4. T2: 3-month follow-up assessment
  5. T3: one-year follow-up assessment
  6. PCL-S: PTSD Checklist – Specific Version, CGI: Clinical Global Impression, MINI-S: Mini International Neuropsychiatric Interview for DSM-5, PDI: Peritraumatic Distress Inventory, PDEQ: Peritraumatic Dissociative Experiences Questionnaire, WHOQOL-BREF: World Health Organization Quality of Life (brief), EQ-5D-5 L: EuroQol Questionnaire, MEDEC: Medico-Economic Questionnaire, HSCL-25: Hopkins Symptom Checklist, QFS: Social Functioning Questionnaire